For reprint rights or to purchase a copy of your Daily Journal photo, email Jeremy_Ellis@dailyjournal.com for prices or call 213-229-5424.

To buy more copies, call 866-531-1492 or email subscribe@dailyjournal.com
This is the property of the Daily Journal Corporation and fully protected by copyright. It is made available only to Daily Journal subscribers for personal or collaborative purposes and may not be distributed, reproduced, modified, stored or transferred without written permission. Please click "Reprint" to order presentation-ready copies to distribute to clients or use in commercial marketing materials or for permission to post on a website. and copyright (showing year of publication) at the bottom.
Subscribe to the Daily Journal for access to Daily Appellate Reports, Verdicts, Judicial Profiles and more...

Mergers & Acquisitions

Apr. 9, 2014

Latham advises Questcor Pharmaceuticals in $5.6B sale to Mallinckrodt

Anaheim-based pharmaceutical developer Questcor Pharmaceuticals Inc. tapped Latham & Watkins LLP in its $5.6 billion sale to Dublin-based drug maker Mallinckrodt Pharmaceuticals PLC.


By Dominic Fracassa


Daily Journal Staff Writer


Anaheim-based pharmaceutical developer Questcor Pharmaceuticals Inc. tapped Latham & Watkins LLP for counsel in its $5.6 billion sale to drugmaker Mallinckrodt Pharmaceuticals PLC, a deal announced Monday.


The combination is expected to expand Mallinckrodt's offering of specialty pharmaceuticals. Questcor's flagship drug, Acthar, is used to treat inflammatory conditions and autoimmune...

To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$895, but save $100 when you subscribe today… Just $795 for the first year!

Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)

Already a subscriber?

Enewsletter Sign-up



By using our website, you agree to our use of cookies in accordance with our cookie policy. You can learn more about how we use cookies by reviewing our Privacy Policy here.